Literature DB >> 15301640

Influences of mood, depression history, and treatment modality on outcomes in smoking cessation.

Amie L Haas1, Ricardo F Muñoz, Gary L Humfleet, Victor I Reus, Sharon M Hall.   

Abstract

The relationship between major depressive disorder (MDD), treatment modality, and mood was evaluated in smokers participating in cessation programs. Participants (N = 549, 53.7% women, 46.3% men, 28% endorsing past MDD episodes) were randomly assigned to a cognitive-behavioral treatment (CBT) or health education (HE) intervention. Participants with a history of recurrent MDD (MDD-R) had higher rates of abstinence in CBT compared with HE even when the contribution of mood and the interaction between mood and an MDD x Treatment variable were included in the model. Likewise, higher levels of mood disturbance were reported by MDD-R smokers compared with those reporting a single episode. The study replicated results reported by R. A. Brown et al. (2001) and expanded upon them by evaluating the differential contribution of poor mood on cessation outcomes relative to MDD history.

Entities:  

Mesh:

Year:  2004        PMID: 15301640     DOI: 10.1037/0022-006X.72.4.563

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  62 in total

1.  Isolating the role of psychological dysfunction in smoking cessation: relations of personality and psychopathology to attaining cessation milestones.

Authors:  Adam M Leventhal; Sandra J Japuntich; Megan E Piper; Douglas E Jorenby; Tanya R Schlam; Timothy B Baker
Journal:  Psychol Addict Behav       Date:  2012-05-28

2.  Positive Psychotherapy for Smoking Cessation: Treatment Development, Feasibility and Preliminary Results.

Authors:  Christopher W Kahler; Nichea S Spillane; Anne Day; Elise Clerkin; Acacia Parks; Adam M Leventhal; Richard A Brown
Journal:  J Posit Psychol       Date:  2014-01-01

3.  Negative affect as a mediator of the relationship between vigorous-intensity exercise and smoking.

Authors:  Candyce D Tart; Teresa M Leyro; Ashley Richter; Michael J Zvolensky; David Rosenfield; Jasper A J Smits
Journal:  Addict Behav       Date:  2010-02-01       Impact factor: 3.913

4.  Nicotine dependence as a moderator of a quitline-based message framing intervention.

Authors:  Lisa M Fucito; Amy E Latimer; Shannon Carlin-Menter; Peter Salovey; K Michael Cummings; Robert W Makuch; Benjamin A Toll
Journal:  Drug Alcohol Depend       Date:  2010-10-30       Impact factor: 4.492

Review 5.  Applying the tripartite model of anxiety and depression to cigarette smoking: an integrative review.

Authors:  Katherine J Ameringer; Adam M Leventhal
Journal:  Nicotine Tob Res       Date:  2010-10-29       Impact factor: 4.244

6.  Bupropion and cognitive-behavioral treatment for depression in smoking cessation.

Authors:  Richard A Brown; Raymond Niaura; Elizabeth E Lloyd-Richardson; David R Strong; Christopher W Kahler; Ana M Abrantes; David Abrams; Ivan W Miller
Journal:  Nicotine Tob Res       Date:  2007-07       Impact factor: 4.244

7.  Anhedonia, depressed mood, and smoking cessation outcome.

Authors:  Adam M Leventhal; Megan E Piper; Sandra J Japuntich; Timothy B Baker; Jessica W Cook
Journal:  J Consult Clin Psychol       Date:  2013-11-11

8.  Smoking processes, panic, and depressive symptoms among treatment-seeking smokers.

Authors:  Dawn W Foster; Kirsten J Langdon; Norman B Schmidt; Michael Zvolensky
Journal:  Subst Use Misuse       Date:  2014-12-15       Impact factor: 2.164

9.  Anhedonia and anxiety sensitivity: prospective relationships to nicotine withdrawal symptoms during smoking cessation.

Authors:  Kirsten J Langdon; Adam M Leventhal; Sherry Stewart; David Rosenfield; Dan Steeves; Michael J Zvolensky
Journal:  J Stud Alcohol Drugs       Date:  2013-05       Impact factor: 2.582

10.  Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice.

Authors:  Astrid K Stoker; Svetlana Semenova; Athina Markou
Journal:  Neuropharmacology       Date:  2008-04-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.